Cover Image

Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis

Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly improve prognosis of advanced NSCLC patients harboring EGFR sensitizing mutation. Howe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yan Lu (Author), Chenbing Sun (Author), Lijing Jiao (Author), Yu Liu (Author), Yabin Gong (Author), Ling Xu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Lijing Jiao, et al.
Published: (2019)

Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial
by: Jialin Yao, et al.
Published: (2022)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
by: Yujia Wang, et al.
Published: (2021)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)

Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond
by: Xin Li, et al.
Published: (2024)

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
by: Dantong Sun, et al.
Published: (2021)

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
by: Xiaohong Liu, et al.
Published: (2024)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer
by: Dehua Liao, et al.
Published: (2022)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
by: Xiaotong Song, et al.
Published: (2023)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
by: Di Wu, et al.
Published: (2022)

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
by: Carmelo Laface, et al.
Published: (2023)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
by: Yue Zeng, et al.
Published: (2022)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
by: Yun Zhang, et al.
Published: (2021)

EGFR mutation testing in non-small cell lung cancer (NSCLC)
by: Fouad Al Dayel
Published: (2012)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
by: Geunho Choi, et al.
Published: (2021)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
by: M. Yoon, et al.
Published: (2016)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
by: Federica Pecci, et al.
Published: (2022)

Prediction of EGFR Mutation Status in Non-Small Cell Lung Cancer Based on Ensemble Learning
by: Youdan Feng, et al.
Published: (2022)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
by: Brian J. Thomas, et al.
Published: (2023)

Impact of the Gastric Acid Suppressant Use on the Safety and Effectiveness of EGFR-TKIs: A Systematic Review and Meta-Analysis
by: Xin Du, et al.
Published: (2022)

EGFR Mutation in Nasopharyngeal Carcinoma
by: Evren Uzun, et al.
Published: (2022)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
by: Fang S, et al.
Published: (2014)

A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma
by: Xue Han, et al.
Published: (2023)

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
by: Haiyan Xu, et al.
Published: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
by: Jing Zhu, et al.
Published: (2021)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
by: Julie M. Janssen, et al.
Published: (2022)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
by: Haoyue Hu, et al.
Published: (2023)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
by: Connor O'Leary, et al.
Published: (2020)

Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non-small cell lung carcinoma
by: Tripti Nakra, et al.
Published: (2021)

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
by: Yap TA, et al.
Published: (2014)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
by: Ki-Chang Lee, et al.
Published: (2021)

Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors
by: Lianbao Ye, et al.
Published: (2019)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021)

The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
by: Hsiang-Ling Ho, et al.
Published: (2019)